Evidence map›Paper›PMID 36997589›Full record

ArticleScientific reports2023

Utilizing genetic code expansion to modify N-TIMP2 specificity towards MMP-2, MMP-9, and MMP-14.

Hezi Hayun, Matt Coban, Ashok Kumar Bhagat, Eden Ozer, Lital Alfonta, Thomas R Caulfield, Evette S Radisky, Niv Papo

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Modeling Lewy body disease withScience advances · 2024
    Article
  5. Non-Canonical Amino Acids in Analyses of Protease Structure and Function.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Hezi HayunAvram and Stella Goldstein-Goren Department of Biotechnology Engineering and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, P.O.B. 653, 84105, Beer-Sheva, Israel.
Matt CobanDepartment of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, 310 Griffin Building, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Ashok Kumar BhagatDepartment of Life Sciences and Ilse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, 8410501, Beer-Sheva, Israel.
Eden OzerDepartment of Life Sciences and Ilse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, 8410501, Beer-Sheva, Israel.
Lital AlfontaDepartment of Life Sciences and Ilse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, 8410501, Beer-Sheva, Israel.
Thomas R Caulfield *Departments of Neuroscience, Artificial Intelligence and Informatics, Computational Biology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Jacksonville, FL, 32224, USA. caulfield.thomas@mayo.edu.
Evette S Radisky *Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, 310 Griffin Building, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. radisky.evette@mayo.edu.
Niv Papo *Avram and Stella Goldstein-Goren Department of Biotechnology Engineering and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, P.O.B. 653, 84105, Beer-Sheva, Israel. papo@bgu.ac.il.
Ben-Gurion University of the Negev · ILMayo Clinic in Florida · USJacksonville College · US

Funding

Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapyR01CA258274 · NCI · MAYO CLINIC JACKSONVILLE · PI RADISKY, EVETTE S · 2021 to 2025
$1.6M
Exploiting new approaches for selective inhibition of trypsinsR01GM144393 · NIGMS · MAYO CLINIC JACKSONVILLE · PI Evette S Radisky · 2022 to 2026
$1.5M
Engineering selective inhibition of metalloproteinases by tissue inhibitors of metalloproteinases (R01 GM132100 RESUB - *TIMPs)R01GM132100 · NIGMS · MAYO CLINIC JACKSONVILLE · PI RADISKY, EVETTE S · 2020 to 2023
$1.3M
NCI NIH HHS R01 CA258274NIGMS NIH HHS R01 GM132100
6 · The paper itself

Abstract

Matrix metalloproteinases (MMPs) regulate the degradation of extracellular matrix (ECM) components in biological processes. MMP activity is controlled by natural tissue inhibitors of metalloproteinases (TIMPs) that non-selectively inhibit the function of multiple MMPs via interaction with the MMPs' Zn

Indexed as

Matrix Metalloproteinase 2Tissue Inhibitor of Metalloproteinase-2LevodopaMatrix Metalloproteinase 14Matrix Metalloproteinase 9Tissue Inhibitor of MetalloproteinasesLevodopaMatrix Metalloproteinase 14Matrix Metalloproteinase 2Matrix Metalloproteinase 9Tissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinases

Identifiers

PMID36997589
PMCPMC10063552
OpenAlexW4361273619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.